This page is referenced by:

• 1 2019-12-04T01:49:10-08:00 BioSig Tech PURE EP™ System 2 plain 2019-12-04T01:49:43-08:00 The rapid increase in the aging population was found to be responsible for increasing heart failure rates, which has further contributed to the growth of the electrophysiology market. Electrophysiology is the biomedical field that deals with the study of electric activity in the body. Electrophysiology includes the study of the generation of electrical activity and the effects of that electrical activity on the body. BioSig Tech’s first product, the PURE EP™ System, is a system designed for use in the large and growing electrophysiology market.
  BioSig Tech PURE EP™ System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system developed to assist electrophysiologists in making clinical decisions in real-time, albeit diagnostic or during an ablation procedure. “We are delighted that our application for an electrophysiology simulator has been allowed by the U.S. Patent & Trademark Office.  We believe that our system may become a valuable assistant in many research and clinical EP labs and may open doors to simulation-guided approaches to advance understanding of current arrhythmia therapies,” stated Kenneth L. Londoner, Founder, Chairman and CEO of BioSig Technologies, Inc.
  
  Refined in collaboration with prestigious institutions such as the Texas Cardiac Arrhythmia Institute, Mayo Clinic, Mount Sinai and UCLA with data presented at world-renowned conferences, the PURE EP System has the potential to shorten procedure time and reduce the necessity for repeated procedures that are frequent with current devices. Recently, the PURE EP System was featured in an article written by researchers from the prestigious Mayo Clinic and published online in The Journal of the American College of Cardiology: Clinical Electrophysiology (JACCCEP).
  
  Many of today's EP systems have limited dynamic range, which translates into problems in needing to amplify small signals in order to see them, which ultimately distorts resolution and saturates large signals. Electrical noise is also an issue, which makes it difficult for clinicians to differentiate real physiologic signals from noise. BioSig's PURE EP System has shown effective in helping to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.
  
  Once approved for marketing, BioSig Tech is entering into a global market for Electrophysiology EP devices, one of the fastest-growing medical device segments. Looking to measure up to the major players currently dominating the market, in January 2018, BioSig Technologies partnered with Mr. Charles Austin and JK Advisors to scale up operational activities. Currently, North America dominates the market for electrophysiology and the region is expected to continue its stronghold for a few more years.